{
  "id": "6417900b690f196b5100002a",
  "type": "factoid",
  "question": "What type of DMD can viltolarsen be used for?",
  "ideal_answer": "Viltolarsen can be used for the treatment of Duchenne muscular dystrophy (DMD) by skipping exon 53 of the DMD gene.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34938127",
    "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
    "http://www.ncbi.nlm.nih.gov/pubmed/33285037",
    "http://www.ncbi.nlm.nih.gov/pubmed/36401027",
    "http://www.ncbi.nlm.nih.gov/pubmed/32453377",
    "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
    "http://www.ncbi.nlm.nih.gov/pubmed/35634851",
    "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
    "http://www.ncbi.nlm.nih.gov/pubmed/31720560",
    "http://www.ncbi.nlm.nih.gov/pubmed/32947786"
  ],
  "snippets": [
    {
      "text": "Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\u00a0for the treatment of Duchenne muscular dystrophy (DMD)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Viltolarsen restores the reading frame of the DMD gene by skipping \u00a0exon 53\u00a0and produces a truncated but functional form of dystrophin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In March 2020, intravenous viltolarsen received its first global approval in Japan for the treatment of DMD in patients with confirmed deletion of the dystrophin gene that is amenable to exon 53 skipping.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\u00a0for the treatment of Duchenne muscular dystrophy (DMD), one of the most common lethal genetic disorders characterized by progressive degeneration of skeletal muscles and cardiomyopathy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Viltolarsen, also known as NS-065/NCNP-01, is a PMO developed through comprehensive sequence optimization and is designed to skip exon 53 on the DMD primary transcript.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31720560",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: The novel morpholino antisense oligonucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystr",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33285037",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Viltolarsen binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Viltolarsen is a drug of phosphorodiamidate morpholino oligomer (PMO) chemistry, designed to skip exon 53 of the DMD gene.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34938127",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Viltolarsen, an AON for DMD exon 53 skipping, was approved in Japan earlier this year.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32483212",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401027",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "en for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years. We are witnessing the sta",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32947786",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importance: An unmet need remains for safe and efficacious treatments for Duchenne muscular dystrophy (DMD). To date, there are limited agents available that address the underlying cause of the disease.Objective: To evaluate the safety, tolerability, and efficacy of viltolarsen, a novel antisense oligonucleotide, in participants with DMD amenable to exon 53 skipping.Design, Setting, and Participants: This phase 2 study was a 4-week randomized clinical trial for safety followed by a 20-week open-label treatment period of patients aged 4 to 9",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32453377",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Duchenne muscular dystrophy (DMD) is a rare, genetic disease caused by mutations in the DMD gene resulting in an absence of functional dystrophin protein. Viltolarsen, an exon 53 skipping therapy, has been shown to increase endogenous dystrophin levels. Herein, long-term (>2 years) functional outcomes in viltolarsen treated patients were compared to a matched historical control group.OBJECTIVE: To evaluate long-term efficacy and safety of the anti-sense oligonucleotide viltolarsen in the treatment of patients wit",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35634851",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Viltolarsen (Viltepso\u00ae in Japan) is a phosphorodiamidate morpholino antisense oligonucleotide being developed by Nippon Shinyaku, in collaboration with the National Center of Neurology and Psychiatry (NCNP), for the treatment of Duchenne muscular dystrophy (DMD). Viltolarsen binds to exon 53 of the dystrophin mRNA precursor and restores the amino acid open-reading frame by skipping exon 53, resulting in the production of a shortened dystrophin protein that contains essential functional portions. In March 2020, intravenous viltolarsen received its first global approval in Japan for the treatment of DMD in patients with confirmed deletion of the dystrophin gene that is amenable to exon 53 skipping.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32519222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Viltolarsen is a phosphorodiamidate morpholino antisense oligonucleotide (PMO) designed to skip exon 53 of the DMD gene\u00a0for the treatment of Duchenne muscular dystrophy (DMD),",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36401022",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "exon 53"
}